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Strategic planningIn South Africa, new drug regimens (WHO treatment Option B) used to manage HIV infection in pregnancy and
the national strategic plan on HIV have resulted in improved health outcomes. Among these outcomes are reduc-
tions in the following:mother-to-child transmission (MTCT) of HIV to 2.4%; maternal deaths attributable to HIV;
and adverse reactions due to antiretroviral therapy (ART). The present article describes these new drug regimens
and the national strategic HIV management plan, as well as their challenges and the implications of improved
health outcomes. Such outcomes imply that further decreases in MTCT of HIV, and HIV attributable maternal
deaths are possible if potential challenges are addressed and treatment option B+offered. A conﬁdential enquiry
into each case of MTCT is advocated to reduce vertical transmission rates to zero levels.
© 2015 Published by Elsevier Ireland Ltd. on behalf of International Federation of Gynecology andObstetrics. This
is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
In 2012, approximately 35.3 (32.2–38.8) million people, 70% of
whom were women, were living with HIV infection worldwide; Sub-
Saharan Africa accounts for 71% of this ﬁgure [1]. In the same year, an
estimated 6.1 million people were living in South Africa with HIV infec-
tion; this constitutes an overall prevalence rate of 17.9%, making South
Africa the country with the highest number of people infected with
this retroviral disease [2]. This has translated to a high burden of HIV
infection among pregnant women. To lessen this burden, new drug
regimens and strategies have been introduced internationally and
across nations. For instance, in 2001 the United Nations developed the
four-pronged framework for the prevention of mother-to-child trans-
mission (MTCT) of HIV. The components of this framework are primary
prevention of HIV infection; prevention of unplanned pregnancies;
prevention of MTCT; and the provision of appropriate care, treatment,
and support to HIV-infected mothers, their children, and families [3].
In an attempt to improve care, South Africa has developedmanagement
guidelines and health policies that have repeatedly been revised based
on emerging evidence and the resources available to the country.
The new antiretroviral drug regimens [4] and national strategic plan
[5] for the management of HIV in pregnancy in South Africa are leading
to improved health outcomes. Notably, the national prevalence of HIV
in pregnancy has declined from 30% in 2010 to 29.5% in 2012 [2]. Data
on the number of HIV-exposed infants who tested polymerase chainResearch Group, University of
75.
behalf of International Federation ofreaction (PCR) positive at approximately two months of age show that
the rate of MTCT has also declined from 9.6% in 2008 to 4.4% in 2010
[6] and to 2.4% in 2013 [7]. The 2013 interim Saving Mothers report
has shown that the institutional maternal mortality ratio in South
Africa has decreased from 176.2 per 100 000 live births in 2008−2010
to 146.7 per 100 000 live births in 2012. The decline in maternal deaths
is attributable to a reduction in the number of deaths resulting from
nonpregnancy-related infections, primarily HIV [8]. Similarly, maternal
deaths resulting from an adverse reaction to antiretroviral therapy
(ART)—nevirapine (NVP) in particular—have also declined [9].
The present article describes South Africa’s new drug regimen and
national strategic plan used for the management of HIV in pregnancy,
their outcomes and challenges, and the implications of further reduc-
tions in MTCT rates.
2. WHO treatment options for prevention of mother-to-child
transmission of HIV
Different ART options have been used for prevention of mother-to-
child transmission (PMTCT) of HIV [10]. In 2012, WHO introduced
three management categories: option A, option B, and option B+ [11].
2.1. Option A
Triple antiretroviral drugs (ARVs) are started following diagnosis
and continued for life (life-long) if the pregnant woman has a CD4
count less than or equal to 350 cells/mm3. Pregnant women with a
CD4 count greater than 350 cells/mm3 receive zidovudine (AZT) fromGynecology and Obstetrics. This is an open access article under the CC BY-NC-ND license
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lamivudine (3TC) during labor; and AZT plus 3TC for seven days post-
partum. The infants of these mothers receive daily NVP for an extra
week following cessation of breastfeeding, or for 4−6 weeks (if not
being breastfed or if the mother is on life-long ARVs).
2.2. Option B
Life-long triple ARVs are started following diagnosis in women with
CD4 less than or equal to 350 cells/mm3. In women with CD4 greater
than 350 cells/mm3, triple ARVs are commenced from 14 weeks of
gestation throughout the prenatal period and stopped after childbirth
(if not breastfeeding), or continued up to one week after cessation of
breastfeeding. The infants of these mothers receive daily NVP or AZT
until they are 4−6 months old irrespective of infant feeding practices.
2.3. Option B+
Every pregnantwoman diagnosed with HIV infection is commenced
on life-long triple ARVs irrespective of CD4 count. The infants of these
mothers receive daily NVP or AZT until they are 4−6 months old re-
gardless of infant feeding practices.
2.4. Rational behind the different treatment options
Treatment options A, B, and B+were suggested byWHO for the fol-
lowing reasons: the global plan to eliminate new cases of HIV infection
in children by 2015 and the need to keep infected mothers alive;
attempt to reduce HIV transmission among discordant couples; opera-
tional challenges associatedwith option A and option B; some countries
proposing their wish to adopt option B+; initiative to simplify ARV
regimen to be exactly the same as the national ﬁrst-line ART for non-
pregnant adults and avoid the need to unnecessarily change ARVduring
a pregnancy; data suggesting that efavirenz is safe in pregnancy; and in-
creasing affordability of ARVs [11]. It has also been established that NVP
causes adverse reactions, especially hepatotoxicity, at baseline CD4
counts of greater than 250 cells/mm3 and greater than 400 cells/mm3
in women [12] andmen [13], respectively. In addition, an increasing in-
cidence of cases of hepatic failure and Stevens-Johnson syndrome has
been detected in pregnant patients on NVP [9]. The availability of a sin-
gle pill containing a ﬁxed-dose combination of tenofovir, lamivudine,
and efavirenz has simpliﬁed the ARV regimen and efﬁciency [11].Table 1
Summary of antiretroviral therapy approved for prevention of mother-to-child transmission o
Recipient Antiretroviral therapy
Mother All pregnant women except those already known to be HIV infected undergo P
women are then managed as outlined below.
Women who are HIV infected are started on ﬁxed-dose combination (FDC) of T
and reviewed in one week.
Women with contraindication to FDC (such as active psychiatric or renal disor
greater than 7 g/dL. Following a review in one week, they are placed on appro
Women on FDC with a baseline CD4 count less than or equal to 350 cell/mm3
Women on FDC with a baseline CD4 count greater than 350 cell/mm3 or WHO
intrapartum period until one week after complete cessation of breastfeeding.
Women having renal impairment with CD4 less than or equal to 350 cells/mm3
than 85 μmol/L, in which case they receive a renal-friendly regimen, AZT + 3T
greater than 350 cell/mm3 or WHO clinical stage 1/2 disease, the patient recei
Women having psychiatric disorder with CD4 less than or equal to 350 cells/m
CD4 greater than 250 cells/mm3). With a CD4 count greater than 350 cell/mm
intrapartum AZT 3 hourly plus sd NVP and sd TDF/FTC.
Women who test HIV positive for the ﬁrst time in labor are given sd NVP plus
Infants
Infants born to HIV-infected mothers receive daily NVP for at least six weeks o
Abbreviations: AZT, Zidovudine; d4T, stavudine; EFV, efavirenz; FTC, emtricitabine; LPV/RTV, l
a Mixed feeding is not a recommended infant feeding option.2.5. Probability of vertical HIV transmission with the use of different
treatment options
There is a scarcity of studies that assess transmission probabilities
when all aspects of each WHO treatment option are addressed in the
targeted population [14,15]. However, use of mathematical models,
such as Spectrum, shows the following MTCT probabilities: single-
dose NVP, 9.4%−12.1%; WHO 2006 dual therapy, 2.3%−5.3%; option A,
2%; option B, 0.9%−2.9%; and option B+, less than 2% [15].
3. New PMTCT drug regimens in South Africa
Theuse of ARVs for PMTCTwasﬁrst introduced in SouthAfrica as na-
tional policy in 2002. The regimen involved the administration of single-
dose NVP to both the mother (during labor) and her newborn (after
delivery). Since then, the PMTCT program was modiﬁed in 2005 and
2008, and option A was introduced in 2010 [16]. Thereafter, option B
was introduced in 2013 and constitutes current practice at the time of
writing the present article [4]. The current drug regimen in South
Africa is similar to WHO option B with the exception that South
African guidelines state that pregnant women with CD4 greater than
350 cell/mm3 are initiated on ART during the ﬁrst prenatal visit, even
before 14 weeks of gestation. This South African drug regimen is satis-
factory (as option B) given the acceptable safety proﬁle of efavirenz in
pregnancy, and that the longer the duration of ART before delivery
then the less chance of MTCT of HIV [17]. Table 1 provides a summary
of the ARV regimen used for PMTCT in South Africa. Further details on
the drug regimens used for PMTCT in South Africa are free to view on-
line [4]. The purpose of the South African PMTCT guidelines is to ensure
that every possible preventable MTCT, using option B, is achieved.
4. South African national strategic plan on HIV
Strategic planning may be deﬁned as “the systematic and organized
process whereby an organization creates a document indicating the
way it plans to progress from its current situation to the desired future
situation” [18]. Several approaches have been used to develop strategic
planning. A common classical method involves the following ﬁve
processes: (1) establishingmission, vision, and values; (2) strategy for-
mulation involving an analysis of internal and external environments,
SWOT (strengths, weaknesses, opportunities, and threats) matrix, stra-
tegic alternatives, areas and objectives; (3) operational planning;
(4) evaluation of results; and (5) strategy reformulation [18].f HIV in South Africa in 2013.
rovider Initiated Counselling and Testing during the ﬁrst prenatal visit. HIV-infected
DF, FTC/3TC, EFV the same day (in the absence of active psychiatric or renal disorder)
der) are started on daily AZT (300 mg) the same day as long as the hemoglobin is
priate regimen.
or WHO clinical stage 3/4 disease, the treatment is continued life-long.
clinical stage 1/2 disease, the treatment is continued throughout the prenatal and
orWHO stage 3/4 are later commenced on FDC unless the serum creatinine is greater
C + EFV for life (but ABC or d4T is used if AZT is contraindicated). With a CD4 count
ves daily AZT prenatally, AZT 3 hourly plus sd NVP and sd TDF/FTC intrapartum.
m3 or WHO stage 3/4 are commenced on life-long TDF + FTC + NVP (or LPV/RTV if
3 or WHO clinical stage 1/2 disease, the patient receives: prenatally AZT daily;
AZT 3 hourly and sd TDF + FTC.
r until one week after cessation of breastfeeding.a
opinavir/ritonavir; NVP, nevirapine; sd, single dose; TDF, tenofovir; 3TC, lamivudine.
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mitted infections, and tuberculosis (2012−2016) is the current and
third strategic plan for the ﬁght against HIV infections [5]. The vision,
goals and objectives, and core indicators of this strategic plan are
shown in Box 1.
The vision is adapted from the “three zeros” on HIV, which is a
20-year vision by UNAIDS [5]. The goals and objectives were drafted
based on evidence-based publications such as the “Know Your
Epidemic” (KYE) report [19]. Each strategic objective has multiple
subobjectives. Enablers that will ensure successful implementation of
the strategic plan include: effective communication; good governance
and functional institutional arrangements; research; and monitoring
and evaluation using core indicators. Costing and ﬁnancing are also
factored into the strategic plan, with estimated annual cost of 1668.07
and 2872.34 billion US dollars in 2012/13 and 2016/17, respectively
[5] (using an exchange rate of US 1$ = ZAR 11.2269).Box 1
National strategic plan on HIV, sexually transmitted infections, and
tuberculosis 2012−2016 in South Africa.
Vision:
• Zero new cases of HIV and TB infections.
• Zero vertical transmissions of HIV.
• Zero preventable mortality related to HIV and TB.
• Zero discrimination related to HIV, TB, and STIs.
Broad goals:
• Use combination of preventive measures to achieve at least
50% reduction in new HIV infection.
• Ensure that not less than 80% of eligible HIV-infected pa-
tients are started on antiretroviral treatment, with at least
70% of them alive and on the treatment five years following
initiation of the therapy.
• Decrease the number deaths from TB and new cases of TB
infection by 50%.
• Provide an accessible and enabling legal framework that
promotes and protects the human right required to support
successful implementation of the national strategic plan.
• Ensure that the self-reported stigma associated with TB and
HIV is reduced by at least 50%.
Strategic objectives:
• Deal with the structural and social barriers related to HIV, TB,
and STI care, prevention, and impact.
• Prevent new TB, HIV, and STI infections.
• Maintain wellness and health.
• Enhance access to justice and improve human rights
protection.
Core indicators:
• Percentage of HIV-positive young men and women aged
15–24 years.
• Percentage of HIV-positive people in key populations such as
sex workers, etc.
• Percentage and number of infants exposed to HIVwhose HIV
test is positive at six weeks and 18 months of ages.
• Incidence and prevalence of TB.
• Adult mortality percentage attributable to TB and HIV.
• Patterns of stigma.
• Retention of patients on ART.
Abbreviations: TB, tuberculosis; STI, sexually transmitted infec-
tions; ART, antiretroviral therapy.The implementation of the strategic plan at every sector of the
country is based on the following principles: (1) all initiatives should
be vision led; (2) initiatives should be scalable and of high impact;
(3) activities should be evidence based; (4) the strategic plans should
be ﬂexible to accommodate necessary changes; (5) multisectoral team-
work that considers local practices is required for success; (6) through
partnership, the strategic plan should be promoted as having country
ownership by all individuals; and (7) the national strategic plan should
be rights based, ensuring human rights and gender equity [5].
In addition, important determinants of HIV infectionwere addressed
in the strategic plan. Social and behavioral determinants include sexual
debut, having multiple sexual partners, condom use, age-disparate coi-
tal relationships, substance and alcohol abuse, and knowledge of risk
perception. The biological determinants include MTCT, medical male
circumcision, prevention of different sexually transmitted infections,
and initiating treatment on eligible HIV-positive patients as a preven-
tive measure. Structural determinants are issues of mobility and migra-
tion, norms and gender roles, and intimate partner violence/sexual
abuse. Further information on South Africa’s national strategic plan on
HIV is free to view online [5].
The ﬁrst evaluation of South Africa’s PMTCT program occurred in
2010 and a 3.5% rate of MTCT was reported [20]. The national strategic
plan on HIV has identiﬁed a need for a strategic plan on HIV for sex
workers [21]. In 2013, this then led to the development of a strategic
plan entitled the “National Strategic Plan for HIV Prevention, Care
and Treatment for Sex Workers” [21]. It is important to note that a
review of the HIV, tuberculosis, and PMTCT programs in South Africa
was carried out in 2013 and was reported in 2014 [22]. This was
aimed to assess the performance of different programs and suggest
measures for improvement. The review showed that MTCT based on
positive PCR at eight weeks of age decreased to 2.6%/2.7% in 2011/
2012 respectively [22].
5. Challenges associated with the South African 2013
PMTCT guidelines
In South Africa there are factors that occasionally prevent the com-
plete implementation of the PMTCT guidelines, and as a result increase
the risk ofMTCT. These factors include booking for prenatal care at a late
gestation, no monitoring of maternal viral load, failure to perform an
HIV test on exposed infants, and inadequate ARV prophylaxis [16].
Others factors include poor quality data collection and management,
failure to obtain any prenatal care, and inability to initiate ARVs at
every public healthcare facility in the country [6]. In addition, over-
crowding of maternity units predispose mothers to HIV transmission
[23]. Gender-based violence and inadequate stafﬁng of health facilities
are also issues of concern.
There are measures that may be valuable in addressing the afore-
mentioned challenges in South Africa. For instance, intensiﬁcation of
community health promotion will encourage citizens to avoid risky
practices. The newly introduced “MomConnect” mobile phone text
message services used to provide healthcare information to pregnant
womenwill also be valuable [24]. Ongoing in-service training ofmedical
staff will improve data management and adherence to the PMTCT
guidelines. It is envisaged that the rollout of the national health insur-
ance scheme [25] will provide the infrastructure and human resources
required to promote health, as well as zero MTCT.
6. Conclusion
In South Africa, new drug regimens and the strategic plan on HIV
have resulted in improved health outcomes such as a reduction in
MTCT of HIV. This has been a major achievement. If the current chal-
lenges associated with implementation of the PMTCT guidelines are
tackled and treatment option B+ adopted, it is hoped that complete
elimination of MTCT will be a reality. Conﬁdential enquiry into each
S22 N.C. Ngene, J. Moodley / International Journal of Gynecology and Obstetrics 131 (2015) S19–S22case of MTCT should be undertaken to identify and address gaps mili-
tating against complete elimination of vertical transmission.
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